Amgen Inc. v. F. Hoffmann-LaRoche LTD et al
Filing
1024
BRIEF by F. Hoffmann-LaRoche LTD, Roche Diagnostics GmbH, Hoffmann LaRoche Inc. (Addition to Bench Memorandum Regarding Relevance and Admissibility of Genentech's PLA). (Attachments: #1 Exhibit A#2 Exhibit B)(Toms, Keith)
<![CDATA[
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al
Doc. 1024 Att. 2
Case 1:05-cv-12237-WGY
Document 1024-3
Filed 09/10/2007
Page 1 of 1
EXHIBIT B to Addition to Bench Memorandum Regarding Relevance and Admissibility of Genentech's PLA
April 7, 1983 November 9, 1983 December 13, 1983 February July 1984 February 17, 1984 February 21, 1984 September 1984February 5, 1985 September 28, 1984 November 2, 1984 U.S. Patent No. 4,766,075 ("the `075 patent") filed. (Admitted Trial Exhibit 2030) EP 0 093 619 ("the `619 EP application") published. (Admitted Trial Exhibit 2029) Lin Patent Application 561,024 filed. Genentech Clinical Study 83-007 "A Controlled Randomized Phase I Trial of Recombinant Tissue-type Plasminogen Activator (rt-PA) in Acute Myocardial Infarction," which included 56 patients. (Trial Exhibit PNT at ROCHE-GNE 01450-51). Genentech Clinical Study 83-007, First heart patient administered recombinant human tPA (Trial Exhibit PNT at ROCHE-GNE 01545) Lin Patent Application 582,185 filed. Clinical trial of recombinant human tPA from Genentech conducted by the National Heart, Lung and Blood Institute in cooperation with Genentech as part of the Thrombolysis in Myocardial Infarction (TIMI) research program. (Trial Exhibit PXY at Roche-GNE 00387). Lin Patent Application 655,841 filed. Final Report for Genentech Clinical Study 83-007 "A Controlled Randomized Phase I Trial of Recombinant Tissue-type Plasminogen Activator (rt-PA) in Acute Myocardial Infarction indicating in vivo biological activity in heart patients ("recanalization rate is excellent") in heart patients. (Trial Exhibit PNT at ROCHE-GNE 01450-51). Lin Patent Application 675,298 filed. Results of TIMI study with Genentech recombinant tPA published in New England Journal of Medicine (Trial Exhibit PXY at ROCHE-GNE 00390, 00428-432).. Genentech "Product License Application For ActivaseTM" ("ActivaseTM PLA") submitted to Food and Drug Administration (Trial Exhibit OUX at ROCHE-GNE 03009).
November 30, 1984 April 4, 1985 April 24, 1986
Dockets.Justia.com
]]>
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?
